6/15/2014 2:59:35 AM
(Reuters) - An executive vice-president of Valeant Pharmaceuticals International Inc (VRX.TO) will leave the company, even as the Canadian drugmaker fends off criticism about management turnover from its takeover target Allergan Inc (AGN.N).
Executive vice-president and company group chairman Ryan Weldon will leave, Valeant confirmed late on Friday after inquiries by Reuters. Like Chief Executive Mike Pearson, Weldon previously worked for management consulting firm McKinsey & Co.
Help employers find you! Check out all the jobs and post your resume.
comments powered by